Search Result

Results for "

antifibrinolytic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) AMPK (2) Autophagy (4) HIV (4) IGF-1R (2) Isotope-Labeled Compounds (5) Mitophagy (2) MMP (3) Phosphodiesterase (PDE) (4)
By Research Areas:	Cancer (10) Cardiovascular Disease (8) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0236

6-Aminocaproic acid 2 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Others	Metabolic Disease Cancer
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-B1258

4-(Aminomethyl)benzoic acid Aminomethylbenzoic acid; α-Amino-p-toluic acid	Amino Acid Derivatives	Cancer
4-(Aminomethyl)benzoic acid is a competitive inhibitor of PepT1 and has antifibrinolytic activity .

HY-B0149S1

Tranexamic acid-d2-1	Isotope-Labeled Compounds	Cancer
Tranexamic acid-d₂-1 is the deuterium labeled Tranexamic acid[1]. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM[2][3].

HY-B0149

Tranexamic acid 1 Publications Verification cyclocapron	IGF-1R AMPK MMP Mitophagy	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-B0149S3

Tranexamic acid-13C2,15N Cyclocapron-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Inflammation/Immunology
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-B0236A

6-Aminocaproic acid hydrochloride EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride	Others	Metabolic Disease Cancer
6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-B0149S

Tranexamic acid-d2	Isotope-Labeled Compounds	Cardiovascular Disease
Tranexamic acid-d₂ is the deuterium labeled Tranexamic acid. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments.

HY-B1258R

4-(Aminomethyl)benzoic acid (Standard)	Amino Acid Derivatives	Others
4-(Aminomethyl)benzoic acid (Standard) is the analytical standard of 4-(Aminomethyl)benzoic acid. This product is intended for research and analytical applications. 4-(Aminomethyl)benzoic acid is an unnatural amino acid derivative and an antifibrinolytic drug.

HY-B0149R

Tranexamic acid (Standard) cyclocapron (Standard)	IGF-1R AMPK MMP Mitophagy	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (Standard) is the analytical standard of Tranexamic acid. This product is intended for research and analytical applications. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-167934

Isomer-CM 352	Others	Neurological Disease
Isomer-CM 352 is a new antifibrinolytic agent with inhibitory activity against matrix metalloproteinases. Isomer-CM 352 effectively reduced hematoma expansion and promoted functional and neurological recovery in a model of intracerebral hemorrhage. Isomer-CM 352 improved neurological function by preventing hematoma growth and showed potential in the suppression of acute neurological diseases .

HY-B0715

Pentoxifylline Maximum Cited Publications 7 Publications Verification BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-B0715S

Pentoxifylline-d6 BL-191-d₆; PTX-d₆; Oxpentifylline-d₆	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5 BL-191-d₅; PTX-d₅; Oxpentifylline-d₅	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-117464

CM-352	MMP	Cardiovascular Disease
CM-352 (compound 5) is an inhibitor of matrix metalloproteinases (MMPs) (MMP-3: IC₅₀=15 nM; MMP-10: IC₅₀=12 nM). CM-352 has significant antifibrinolytic activity (EC₅₀=0.7 nM) and can significantly prolong blood coagulation time. CM-352 can be used in anti-bleeding research .

HY-B0715R

Pentoxifylline (Standard) BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)	HIV Autophagy Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-B0236S1

6-Aminocaproic acid-d10 EACA-d₁₀; Epsilon-Amino-n-caproic Acid-d₁₀; 6-Aminohexanoic acid-d₁₀	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236S

6-Aminocaproic acid-d6 EACA-d₆; Epsilon-Amino-n-caproic acid-d₆; 6-Aminohexanoic acid-d₆	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0236

6-Aminocaproic acid 2 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name	Chemical Structure

HY-B0149S1

Tranexamic acid-d2-1
Tranexamic acid-d₂-1 is the deuterium labeled Tranexamic acid[1]. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM[2][3].

HY-B0715S

Pentoxifylline-d6
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d6

Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d5

Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0236S

6-Aminocaproic acid-d6
6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

6-Aminocaproic acid-d6

6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0149S3

Tranexamic acid-13C2,15N
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-B0149S

Tranexamic acid-d2
Tranexamic acid-d₂ is the deuterium labeled Tranexamic acid. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments.

HY-B0236S1

6-Aminocaproic acid-d10
6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

6-Aminocaproic acid-d10

6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks